Human Chorionic Gonadotropin Test Market Size

Human Chorionic Gonadotropin (HCG) Market size was valued at USD 741.27 million in 2023 and is anticipated to cross USD 1.70 billion by the end of 2036, registering more than 6.6% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of human chorionic gonadotropin is estimated at USD 780.41 million.

The increasing infertility rate globally, along with the growing investment in the innovation of technologically improved products are expected to fuel the development of this market. The growth of the market can also be attributed to factors such as the increasing awareness among the population towards gynaecological problems and the rising middle-class population in the emerging economies on a global level. According to the data collected from the World Health Organization (WHO), in September 2020, approximately 48 million couples and 186 million individuals across the globe lives with infertility. Such increasing number of infertility rate has rapidly increased the requirement for human chorionic gonadotropin (HCG) in the market. The rising shift of traditional lifestyles to western lifestyle adoption along with poor dietary habits among individuals are expected to make a significant contribution to the soaring revenue of the human chorionic gonadotropin (HCG) market. Gynaecology is one of the important branch of medicine concerned with medical issues among women. As a result, it includes conditions associated to wellbeing of women and their testing and screening methodology. Women’s body is predominantly prone to various types of cancer, including, breast cancer, cervical cancer, and ovarian cancer. Other rising medical conditions such as polycystic ovarian disorder, infertility, menopause, depression, osteoporosis, and obesity. Human chorionic gonadotropin (hGC) is a hormone produced by placenta in a pregnant women and is a type of gonadotropin hormone.